The pain reliever Ketorolac tromethamine is a non-narcotic analgesic. It is an NSAID that exhibits anti-inflammatory and weak antipyretic activity. Ketorolac tromethamine inhibits prostaglandin synthesis and is considered a peripheral analgesic. It has no known effect on opiate receptors. After the use of ketorolac tromethamine in controlled clinical trials, no phenomena were observed that would indicate respiratory depression. Ketorolac tromethamine does not cause pupillary constriction.
Short-term treatment of moderate pain, including postoperative pain.
Hypersensitivity to ketorolac or other components of the preparation.
Active ulcer, recent gastrointestinal bleeding or perforation, peptic ulcer, or history of gastrointestinal bleeding
It is advisable to take the tablets during or after meals. The preparation is recommended only for short-term use (up to 5 days). In order to minimize side effects, the preparation should be used in the lowest effective dose for a short period of time necessary to control symptoms. Before starting treatment, it is necessary to achieve normovolemia. For adults, Ketanov should be prescribed 10 mg every 4-6 hours if necessary. It is not recommended to use the preparation in doses exceeding 40 mg per day. Opioid analgesics (for example, morphine, pethidine) can be used in parallel, ketorolac does not affect the binding of opioid preparations and does not increase respiratory depression or sedation caused by opioids. It was demonstrated that in cases of postoperative pain - the simultaneous use of ketorolac with opioid analgesics reduced the need for the latter. For patients who receive parenteral ketorolac and who are destined to oral ketorolac in tablet form, the total combined daily dose should not exceed 90 mg (60 mg for the elderly, patients with impaired renal function and patients weighing less than 50 kg), and the dosage the oral form of the preparation should not exceed 40 mg per day if the use of the form of release of the preparation is changed. Patients should be switched to oral administration of the preparation as early as possible. if the use of the form of release of the preparation is changed. Patients should be switched to oral administration of the preparation as early as possible. if the use of the form of release of the preparation is changed. Patients should be switched to oral administration of the preparation as early as possible.
Elderly patients.
Elderly patients have a greater risk of developing severe complications, in particular from the digestive tract. During treatment with NSAIDs, the patient's condition should be monitored regularly, usually a longer interval between the use of the preparation, for example 6-8 hours, is recommended.
Symptoms: headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding; rarely - diarrhea, disorientation, agitation, coma, drowsiness, dizziness, ringing in the ears, loss of consciousness, convulsions. In cases of severe poisoning, acute renal failure and liver damage are possible.
Treatment: gastric lavage, intake of activated charcoal. Adequate urine output must be ensured. Renal and liver function should be carefully monitored. Patients should be monitored for at least 4:00 after ingestion of a potentially toxic amount. Frequent or prolonged seizures should be treated with diazepam. Other measures may be prescribed depending on the clinical condition of the patient. SPECIAL. Dialysis does not remove ketorolac from the circulation.
Use during pregnancy or lactation
The safety of ketorolac during pregnancy in humans has not been established. Given the known effect of NSAIDs on the fetal cardiovascular system (risk of premature closure of the ductus arteriosus), ketorolac is contraindicated during pregnancy, labor and childbirth. The onset of labor can be delayed, and the duration is lengthened, with an increased tendency for bleeding in both the mother and the baby.
Ketorolac passes into breast milk at low levels, therefore Ketanov is contraindicated during breastfeeding.
Children
Do not use in children under 16 years of age.
The ability to influence the reaction rate when driving or driving other mechanisms
Some patients in the case of using ketorolac may feel drowsiness, dizziness, insomnia, fatigue, visual impairment or depression. If patients feel the above or other similar effects, they should not drive or operate machinery.
active substance: ketorolac tromethamine;
1 coated tablet contains ketorolac tromethamine 10 mg
Excipients: microcrystalline cellulose, corn starch, colloidal silicon dioxide, magnesium stearate, polyethylene glycol 400, talc, titanium dioxide (E 171).
Store in its original packaging at a temperature not exceeding 25 ° C, out of the reach of children.
Shelf life is 3 years.
There are no reviews for this product.